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Lesch–Nyhan disease (LND) is caused by deficiency of the purine salvage enzyme hypoxanthine-guanine phos-
phoribosyltransferase (HPRT). Affected individuals exhibit over-production of uric acid, along with a charac-
teristic neurobehavioural syndrome that includes mental retardation, recurrent self-injurious behaviour and
motor disability. Prior studies involving relatively small numbers of patients have provided different conclusions
on the nature of the motor disorder. The current study includes the results of a multi-centre international
prospective study of the motor disorder in the largest cohort of patients studied to date. A total of 44 patients
ranging from 2 to 38 years presented a characteristic motor syndrome that involved severe action dystonia
superimposed on baseline hypotonia. Although some patients also displayed other extrapyramidal or pyramidal
signs, these were always less prominent than dystonia. These results are compared with a comprehensive
review of 122 prior reports that included a total of 254 patients. Explanations for the differing observations
available in the literature are provided, along with a summary of how the motor disorder of LND relates to
current understanding of its pathophysiology involving the basal ganglia.
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Introduction
Lesch–Nyhan disease (LND) is an X-linked recessive disorder
caused by deficiency of the purine salvage enzyme
hypoxanthine-guanine phosphoribosyltransferase (HPRT).
Affected individuals have hyperuricaemia and a characteristic
neurobehavioural phenotype that includes mental retarda-
tion, self-injurious behaviour and motor disability (Lesch
and Nyhan, 1964; Jinnah and Friedmann, 2000). A number
of detailed studies have addressed the genetic (Jinnah et al.,
2000; Jinnah et al., 2004), metabolic (Seegmiller, 1989; Jinnah
and Friedmann, 2000; Puig et al., 2001), cognitive (Anderson
et al., 1992; Matthews et al., 1995; Schretlen et al., 2001) and
behavioural (Nyhan, 1976; Anderson and Ernst, 1994; Robey
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et al., 2003; Schretlen et al., 2005) features of this disease. In
comparison, fewer studies have specifically addressed the
motor disorder.
In their original report of two affected brothers in 1964,
Lesch and Nyhan described choreoathetosis and increased
muscle tone as the salient motor abnormalities (Lesch and
Nyhan, 1964). Subsequently, several retrospective studies
described larger numbers of patients. The largest of these
included 19 patients, all of whom were described as having
choreoathetosis, with a minority also having dystonia
(Christie et al., 1982). All of these patients were described as
also showing signs of corticospinal dysfunction, such as scissor-
ing of the legs or extensor plantar reflexes. The second largest
series included 14 patients, most of whom were described as
having choreoathetosis and spasticity (Mizuno, 1986). In keep-
ing with these reports, most modern textbooks of paediatric
neurology emphasize choreoathetosis and pyramidal signs in
their descriptions of LND. However, one of the most detailed
studies that included eight patients described dystonia rather
than choreoathetosis as the major motor abnormality (Watts
et al., 1982). All of these patients also were described as
having hypotonia rather than hypertonia, and pyramidal
signs were uncommon. Another five patients were described
as showing a combination of choreoathetosis, dystonia, ballis-
mus and ataxia (Jankovic et al., 1988). Pyramidal signs were
not noted in these patients. Finally, many reports of smaller
numbers of cases have described various combinations of
choreoathetosis, dystonia, ballismus, spasticity, hypotonia or
ataxia. The reasons for these incongruent descriptions of the
motor disorder of LND remain unclear.
To further delineate the motor disorder of LND, 44
patients from 40 different families were evaluated system-
atically by the same group of investigators using defined
criteria for the diagnosis of motor disorders. The evaluations
revealed a relatively uniform motor phenotype that consists
of severe generalized dystonia superimposed on hypotonia,
sometimes with less prominent choreoathetosis or spasticity.
These results are compared with a comprehensive review of
the published literature, and the potential reasons for the
differing descriptions are considered. The motor phenotype
is also considered in the light of current knowledge of patho-
physiology in LND.
Methods
Prospective evaluation
This study included 44 LND patients. They were recruited after
referral for clinical evaluation and management, after referral to
centres devoted to the long-term care of patients with developmental
disabilities or metabolic diseases, or after participation in other
studies. A detailed assessment of the motor syndrome has not
been reported for the current patients, excepting no. 29 (De
Gregorio et al., 2005). Some of the results have been summarized
in abstract form (Jinnah et al., 1998; Visser et al., 2004).
The focus of this study was on the motor features of classic LND
due to complete HPRT deficiency. A definitive molecular (hprt
gene mutation predicting null enzyme function) or biochemical
(<1% residual HPRT enzyme activity in blood or fibroblast samples)
diagnosis was established for 40 of 44 patients. Of the remaining four
patients, three declined laboratory confirmation and one died before
testing could be arranged. Among these four patients were three who
met clinical criteria for LND with expression of the full syndrome
including mental retardation, self-injurious behaviours, motor dis-
ability and over-production of uric acid. The remaining patient
(no. 3) exhibited the full syndrome except for self-injurious beha-
viours. This patient was included because he had a cousin who was
diagnosed with LND on the basis of the full clinical syndrome that
included self-injury. Because the focus of this study was on the
classic form of the disease due to complete HPRT deficiency, atte-
nuated or partial forms of the disease known to be due to partial
HPRT deficiency were excluded. Only one patient with classic LND
who was evaluated for these studies was excluded, because of an
incomplete record.
The first author directly evaluated 33 of the 44 patients. The
remaining nine patients were evaluated by clinicians who had experi-
ence in movement disorders or had worked with the first author
during evaluation of other LND cases. Detailed videotapes available
for three of these patients were reviewed by the first author to con-
firm diagnostic impressions. The evaluation began with a complete
history. Before their evaluation for this study, many patients had
been evaluated only once by a general neurologist and subsequently
followed in institutions or clinics devoted to paediatrics or metabolic
diseases. Therefore, historical records on the evolution of neurolo-
gical symptoms and signs were not always available.
The examination consisted of a standardized written protocol
with specific attention to the motor features. Video recordings of
the examination were made for 33 patients. All movement disorders
and assessments of muscle tone were defined according to standard
published criteria (Barbeau et al., 1981; Fahn, 1988; Jankovic and
Fahn, 1998; Sanger et al., 2003). Ballism was defined as involuntary
rapid flinging movements, typically of the limbs. Choreoathetosis
was defined as involuntary non-rhythmic and unpatterned move-
ments with variable timing and distribution. Dystonia was defined as
involuntary, sustained, patterned and sometimes repetitive contrac-
tions of opposing muscles often leading to twisting movements or
abnormal posturing. Spasticity was defined as an abnormality of
muscle tone with a velocity-dependent increase in resistance to
externally imposed movement, often worse in extension than flex-
ion. The determination of spasticity was made independent from
other pyramidal signs. Dystonia was discriminated from spasticity
by the lack of velocity-dependence, exaggeration by attempted
action and frequently marked variation in tone with emotional
state (Sanger et al., 2003).
This study is primarily descriptive, but to obtain an estimate of
the severity of individual motor defects for comparative purposes,
we applied a semi-quantitative rating scale that was modelled after
one used in a prior study of LND (Jankovic et al., 1988). The scale
was defined as follows: 0 = motor abnormality absent; 1 = motor
abnormality mild and insufficiently severe to be significantly dis-
abling; 2 = motor abnormality moderate with significant disability
but most functions still possible with added effort; 3 = motor
abnormality severe enough to preclude meaningful function.
Literature review
The Medline database through December 2005 was reviewed for
reports that included the keywords Lesch–Nyhan or hypoxanthine-
guanine phosphoribosyltransferase. Additional patients were
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identified by surveying the reference lists of these and other articles.
A list of the 122 reports reviewed is available from the authors by
request. The clinical data were recorded in a database, and informa-
tion for patients reported more than once was combined into a
single entry wherever possible. Because the focus of this study is
on the classic form of the disease, reports of attenuated variants due
to partial enzyme deficiency were again excluded. Because the dis-
order is X-linked and recessive, virtually all cases were male, and the
rarely reported female cases were excluded.
Prospective evaluation
Demographics
The 44 patients ranged from 2 to 38 years (Table 1). They
were followed for an average duration of 3.3 years (range
0–18 years). All but one of the patients were male. The female
patient had a clinical phenotype indistinguishable from that
of the males.
Medication use at evaluation
All but one patient were receiving allopurinol for control of
uric acid. Twelve were receiving medications to alkalinize the
urine to promote uric acid solubility. Eleven were taking
medications for gastro-oesophageal reflux.
Seven were taking medications to reduce muscle tone
(baclofen, dantrolene, paracetamol). Nineteen were taking
benzodiazepines to alleviate both increased muscle tone
and mood lability (diazepam, clonazepam, alprazolam).
Seven were taking dopamine receptor antagonists (risperi-
done, thioridazine, olanzepine) for control of self-injury
and two were taking metaclopramide to promote gastroin-
testinal motility. Eleven were taking medications for mood
stabilization or depression (paroxetine, gabapentin, carbama-
zepine, clomipramine, sertraline). Though this study was not
designed to assess treatment responses, none of these med-
ications was clearly associated with a dramatic improvement
of the motor disorder. Motor abnormalities among those
taking dopamine receptor antagonists were similar to those
who had never taken them.
Presentation and developmental
progression
Information concerning presenting signs was available from
the histories in 39 patients. All but two first came to medical
attention for motor delay (Table 1). Motor delay became
apparent most often at 3–6 months of age as hypotonia,
with failure to sit upright unsupported. Overt involuntary
movements most often were noted between 6 and 12 months
of age, although abnormal movements sometimes were
appreciated by parents or caretakers earlier, or delayed for
up to 4 years.
After some evolution during the first few years, the severity
of the motor disorder appeared relatively static rather than
progressive in most cases. The majority of patients were
reviewed more than once over a period of several years,
and progression of the motor disorder was not significant
beyond 5–6 years of age. The oldest patients did not appear to
be more seriously affected than the youngest ones. However,
several patients evidenced signs of increasing disability from
long-standing abnormal movements. For example, three
patients had histories noting objective signs of worsening
motor function, such as loss of grasp or ability to stand
with assistance, often in a stepwise fashion. Six developed
severe scoliosis, and one required a surgical procedure to
stabilize the spine.
Only two patients presented first with difficulties attribu-
table to excessive production of uric acid. One presented with
lactic acidosis, presumably due to nephrolithiasis with
obstruction of urine flow and renal failure. The other pre-
sented with orange crystals in the diapers, most probably due
to crystalluria combined with microhaematuria. No patient
presented with self-injurious behaviours, which consistently
emerged later than the other problems, usually between 1 and
8 years of age.
Extrapyramidal signs
Abnormal movements were relatively minor at rest in all
patients, and became most obvious with stress, excitement,
anticipation or voluntary movement. The most prominent
feature of the motor syndrome in all patients was dystonia
(Table 2, Fig. 1). Essentially, all parts of the body were
affected. Multidirectional cervical dystonia was universal.
Truncal twisting and arching was present in all, particularly
with efforts to stand. Dystonia of the upper limbs prevented
their use for most tasks such as feeding or grasping in all
patients. All regularly used wheelchairs because lower limb
dysfunction prevented them from walking or standing unas-
sisted. Oromandibular and lingual dystonia were evident dur-
ing speaking or eating in most. Several also exhibited
blepharospasm, most prominently during ocular testing. Sev-
eral developed fixed abnormal postures of the hands or feet,
and fixed contractures of the hamstring muscles with incom-
plete extension at the knee were common. Muscle hypertro-
phy resulting from long-standing dystonia was evident in
several patients in the neck and arms.
Severe opisthotonus or truncal arching was observed
directly in 11 (25%), and movements compatible with
opisthotonus were described frequently in the medical
records as severe or prolonged ‘arching’ or ‘backward bend-
ing’ of the trunk. Sudden and rapid backward thrusting of the
head without concomitant truncal involvement was observed
directly in four and described in the records of several others.
Such spasms were absent at rest, but emerged when patients
attempted to stand or were transferred from the seated to
supine position. Severe, sustained truncal arching with dys-
tonic tremor sometimes resembled a generalized epileptic
seizure, except that consciousness was preserved and there
was no post-ictal depression of consciousness.
Although dystonia was universal and always the most
severe extrapyramidal disorder, choreoathetosis was present
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in 22 (50%) and ballism was observed in 13 (30%). Ballism
was most common in the arms, though it occasionally
appeared in the legs. These movements were seen almost
exclusively with excitement or agitation. Ballism was often
triggered by the presence of an object near enough to strike,
raising the question of whether this represented impulsive or
voluntary acts of aggression. However, the movements other-
wise appeared typical of ballism, and their speed and fluidity
contrasted with the marked impairment in all other voluntary
movements.
Resting muscle tone
When fully relaxed, 40 (91%) patients were considered to
have hypotonia (Table 2; Fig. 1). Spasticity was noted in
10 (23%) patients. In six of these the spasticity was limited
to the legs, and in three others it was markedly asymmetrical.
Rigidity was noted in six (14%), but cogwheeling was not
apparent.
Corticospinal tract signs
A total of 23 patients (52%) had pathologically brisk muscle
stretch reflexes (Table 2). Pathological reflexes were limited to
the legs in 17 of these patients, and they were asymmetrical in
5. Clonus was observed in 14 (32%) cases, and in 13 of these
cases it was limited to the legs.
Several patients demonstrated an abnormal resting posture
of the great toe. In some, the toe was plantar flexed and
deviated laterally at the metacarpophalangeal joint in a
fixed position above or below the adjacent toe. In others,
the toe remained in extension for lengthy periods without
plantar stimulation, but eventually returned to a normal
position. Plantar stimulation often led to varied responses,
with an extensor on some occasions and a flexor on others.
These phenomena were considered more characteristic of a
striatal toe response than a classic Babinski sign, but distinc-
tion between these signs was not attempted.
Dysarthria and dysphagia
Speech was delayed in all patients for whom developmental
histories were available. Most began using words by 2–4 years
of age. A few were not speaking at much older ages, such as
one who was still not using words by age 14 years.
When speech occurred, it was always dysarthric. In all
patients, dysarthria was severe enough that speech was diffi-
cult to understand without frequent repetition. One was
anarthric because of extreme cervical and oromandibular
dystonia but communicated effectively with a keyboard.
Most communicated using only single words or very short
phrases. Speech had the typical characteristics of striatal dys-
arthria, with slow and irregular enunciation associated with
excessive activation of pharyngeal, lingual, and perioral mus-
cles. During casual conversation, a trailing volume was com-
mon and sufficiently soft to be considered pathologically
hypophonic in 10 (23%) patients, and 2 (4%) of these also
exhibited stuttering without obvious jaw dystonia. Spasmodic
dysphonia with intermittent breathiness, intermittent
strained-strangled quality or phonic breaks was not apparent.
None had a high-pitched, nasal or strained-strangled quality
suggestive of spastic dysarthria. None displayed poor modula-
tion of tempo or volume suggestive of cerebellar dysarthria.
Chewing and swallowing was laboured in most patients.
Many also had gastro-oesophageal reflux with frequent
emesis (Table 1). Together, these problems were sufficiently
severe to require gastrostomy tube in nine (20%) patients.
Other features
Respiratory abnormalities were evident in several patients.
Two patients had prominent inspiratory stridor without
Fig. 1 Summary of the motor signs in current series of 44 LND
patients. The most common signs were extrapyramidal (A),
abnormalities of resting tone (B) and pyramidal signs (C).
Overlapping hatch marks show patients with overlapping signs.
The extensor plantar reflex was omitted because it could not be
unequivocally distinguished from the striatal toe response.
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cyanosis or apnoea during examination and another had a
history of recurrent ‘noisy breathing’ (Table 2). In all three
patients, the respiratory problems were noted during wake-
fulness and not during sleep. Two other patients had frequent
episodes of apnoea and cyanosis without stridor, also during
wakefulness but not during sleep. Extensive pulmonary eva-
luations were normal for both, and EEG studies provided no
evidence for epilepsy. Two other patients each had at least one
episode of cardiopulmonary arrest leading to multiple hos-
pitalizations, and extensive evaluations failed to disclose a
cause. One of these patients expired without obvious
cause, presumably due to an unwitnessed respiratory
event. Another case with no history of cardiopulmonary
events expired during sleep with no apparent cause.
Three patients had histories compatible with generalized
tonic–clonic epileptic seizures, though none was witnessed by
the evaluators, and the possibility of prolonged opisthotonic
posturing with dystonic tremor could not be excluded. One
case had episodic and briefly sustained upwards or lateral
conjugate eye deviation resembling ocular tics. Two cases
with a history of neuroleptic use exhibited repetitive orobuc-
colingual stereotypies typical of tardive dyskinesia. Other tics
or stereotypies were absent. None of the patients had evidence
for cerebellar dysfunction such as appendicular or axial ataxia
or ocular dysmetria. Tremor and myoclonus were absent.
Literature review
Reported cases
A total of 122 reports describing 254 LND patients reported
from 1959 to 2005 were examined. Overall, the average age at
presentation was 6.1 months, with a range of 1 day to 7 years.
The average age at the time of case description was 9.5 years,
with a range of 1 day to 33 years.
Presentation
At least one presenting problem was recorded for 158 patients,
and 130 of these included neurological problems (Table 3).
The most common presenting problems were signs of motor
delay, abnormalities of muscle tone or ‘cerebral palsy’. These
descriptions are not mutually exclusive, as all indicate abnor-
mal motor development. Less common neurological presen-
tations included opisthotonus, apparent epileptic seizures,
‘spastic torticollis’, fisting of the hands, scissoring of the
legs, nystagmus and microcephaly.
Presenting problems among the remaining patients were
due mostly to excessive production of uric acid (Table 3).
Most commonly, these included renal failure or uric acid
crystals in the urine. Gout was uncommon, being noted as
the presenting feature for only three patients. Only two
patients presented with self-injury. A few patients were
noted to present with such non-specific problems as ‘colic’,
‘irritability’ or difficulty feeding. A few pre-symptomatic
patients also were identified because of a known affected
relative.
Developmental progression
No prospective studies of the evolution and natural history of
LND have been reported. However, in one retrospective study
of eight patients followed for up to 8 years, most presented
with hypotonia and/or motor delay between 3 and 9 months
of age, and then developed dystonia between 6 and 24 months
of age (Watts et al., 1982). Another study of six patients
followed over several years provided a similar picture of
early motor delay followed by development of athetosis
and spasticity (Michener, 1967). Limited information con-
cerning the natural history of neurological features was
reported for a total of 69 patients. The most frequently
noted initial neurological problems included hypotonia
and delayed motor development. Involuntary movements
or spasticity usually were not present at birth, but emerged
at an average of 16 months (range 1 month to 6 years).
Involuntary movements or spasticity then appeared to
remain static, as few were described as showing progressive
motor dysfunction beyond 2 years.
Neurological features
A summary of all neurological features noted at the time each
case was reported is provided in Table 4. The neurological
features were described with varying degrees of detail. No
information concerning the neurological features was
Table 3 Presenting features in reported cases
Presenting feature Number
(n = 158)
Per cent
of total
Neurological 130 82.3
Developmental delay 92 58.2
Cerebral palsy 19 12.0
Hypertonia 12 7.6
Hypotonia 8 5.1
Opisthotonus 4 2.5
Seizures 2 1.3
Other* 8 5.1
Urate over-production 18 11.4
Renal failure 8 5.1
Crystalluria 5 3.2
Gout 3 1.9
Other† 3 1.9
Other 21 13.3
Vomiting 6 3.8
Affected family 6 3.8
Colic or irritability 6 3.8
Other‡ 2 1.3
This table summarizes the presenting features in 158 of the 254
cases for whom information was available. A list of the reports
reviewed is available by request. The number of cases may sum to
more than the total because more than one presenting feature
was recorded for several cases. *Includes fisting of the hands,
scissoring of the legs, nystagmus, microcephaly, ‘spastic torticollis’
and ‘abnormal tone’; †includes hyperuricaemia, kidney stone
without renal failure, and acidosis; ‡includes unexplained
fevers and non-specific terminology such as ‘poor feeding’ or
‘lethargy’.
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provided for 34 patients. A detailed description of the neu-
rological features was available for only 42 patients. Among
the 220 patients for whom any neurological information was
provided, various extrapyramidal signs were described. These
included chorea, choreoathetosis, athetosis, dystonia,
opisthotonus and ballismus. Most patients were reported
to have more than one extrapyramidal sign. Other features
commonly reported as pyramidal signs included spasticity,
hyperreflexia, an extensor plantar reflex, scissoring of the legs
and clonus.
Descriptions of muscle tone varied. Among the 96 patients
for whom muscle tone was described, hypertonia was noted
in 69%, hypotonia in 46% and both hypotonia and
hypertonia in 14 of these patients. Increased muscle tone
was most often described as spasticity or dystonia, although
such non-specific terms as ‘hypertonic’ or ‘stiffness’ were
used for several cases. Only three patients were described
as having rigidity.
Uncommonly reported neurological features included
apparent epileptic seizures, ataxia, unspecified dyskinetic
movements and myoclonic-like limb jerks. Varying degrees
of self-injurious behaviours were documented for nearly
all patients but other motor stereotypies and motor or
vocal tics were not apparent. None was reported to have
tremor.
Neuroimaging
Brain CT scans have been reported for 22 patients, including
12 that were part of a retrospective study (Table 5). Atrophy
was reported for four, with the remainder being interpreted
as normal. Results of brain MRI have been reported for
25 patients. Only three were noted to have visible atrophy.
However, a 17% reduction of total cerebral volume and 34%
reduction in basal ganglia volumes were found in a quanti-
tative study when seven patients were compared with normal
controls (Harris et al., 1998).
Although most reports use the term ‘atrophy’ to describe
cerebral volume loss, concurrent enlargement of the cranial
sinuses in one imaging study suggested that the volume loss
reflects poor brain development rather than a degenerative
process (Harris et al., 1998). Therefore, the term ‘dystrophy’
might be more appropriate.
Autopsy reports
Autopsies including brain have been reported for a total of
23 LND patients (Table 6). These studies have not revealed
any consistent neuropathological changes. Notably, complete
neuropathological studies were entirely unremarkable for six
patients, including electron microscopic studies for at least
two. Though multiple different abnormalities have been
reported, the lack of consistency suggests that many of the
findings may be incidental or related to other events occur-
ring at the time of death.
Discussion
Although a literature review suggests considerable variation
in the motor disorder of LND, our evaluation of the largest
series of patients currently available demonstrates a charac-
teristic motor syndrome with only minor phenotypic varia-
bility. The motor disorder characteristically evolves in a
manner similar to that of dyskinetic cerebral palsy, with
hypotonia and/or delayed acquisition of motor skills within
the first 3–6 months of age. Involuntary movements usually
develop between 6 and 24 months of age. Once fully devel-
oped, the clinical course remains relatively static with severe
action dystonia superimposed on a baseline of hypotonia.
Many also display choreoathetosis or ballismus, but these
features are always less severe than dystonia. Although
many have pathological reflexes or spasticity, few have clonus.
When these pyramidal signs are evident, they typically are
mild, limited to the legs or asymmetrical.
Comparison with prior studies
The relatively consistent motor syndrome observed in our
prospectively evaluated patients contrasts with the varied
descriptions of motor abnormalities reported previously
Table 4 Neurological features in reported cases
Feature Number
(n = 220)
Per cent
of total
Extrapyramidal 178 80.9
Choreoathetosis 106 48.2
Opisthotonus 58 26.4
Dystonia 51 23.2
Athetosis 51 23.2
Ballism 12 5.5
Chorea 7 3.2
Pyramidal 145 65.9
Spasticity 118 53.6
Hyperreflexia 61 27.7
Extensor plantar 31 14.1
Scissoring legs 28 12.7
Clonus 11 5.0
Abnormal muscle tone 96 43.6
Hypotonia 44 20.0
Hypertonia 66 30.0
Hypotonia and hypertonia 14 6.4
Other 84 48.1
Dysarthria 67 30.5
Dysphagia 8 3.6
Seizures 18 8.2
Ataxia 8 3.6
Rigidity 4 1.8
This table summarizes the neurological features in 220 of the 254
cases for whom information was available. The number of cases
or percentages may sum to more than the total because more
than one feature was recorded for several cases. The table
employs the terminology in the original published reports with no
attempt to combine similar or overlapping terms such as chorea
and choreoathetosis. The extensor plantar reflex and scissoring
of the legs are listed as pyramidal signs in accordance with the
published reports, though they may also be considered
extrapyramidal as noted in the text.
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and reviewed in this study. One possible explanation for this
discrepancy is that most cases were reported in non-
neurological journals, often with only brief neurological eva-
luations made by examiners with little or no formal training
in the diagnosis of motor disorders. It is widely recognized
that the terminology of movement disorders has been applied
using different criteria by different medical subspecialties for
many years, and many of the reports on LND patients were
published before the establishment of standard definitions
and criteria for many motor disorders (Barbeau et al.,
1981). Some uncertainties concerning nomenclature, parti-
cularly those relating to muscle tone in children, have per-
sisted even after these definitions were established. These
uncertainties have prompted recent efforts to clarify them
further (Delgado and Albright, 2003; Sanger et al., 2003).
To minimize difficulties associated with nomenclature,
each case in the current series was examined by at least
one neurologist with special training in movement disorders,
using currently accepted criteria for diagnosis of abnormal
motor syndromes.
Another reason for the inconsistent descriptions of the
motor syndrome in LND is that some manifestations of
dystonia closely resemble other neurological signs often asso-
ciated with dysfunction of the corticospinal motor systems.
Several major signs have been cited as evidence for cortico-
spinal dysfunction in LND, including spasticity, the extensor
plantar reflex, scissoring of the legs, hyperreflexia and clonus.
The increased muscle tone of dystonia is readily mistaken for
spasticity without special attention to their discriminating
features. The extensor plantar reflex, or Babinski sign, is
not a reliable indicator of corticospinal dysfunction among
patients with extrapyramidal disease, because it cannot be
reliably discriminated from the striatal toe, which is a
form of dystonia (Nausieda et al., 1980; Jan, 2004; Ashour
et al., 2005). Scissoring of the legs is typical in corticospinal
dysfunction but also occurs with severe dystonia (Jankovic
and Fahn, 1998; Furukawa et al., 2001). The many different
manifestations of dystonia are not as well recognized as the
more common manifestations of spasticity among evaluators
without training in movement disorders, and they therefore
are often mistaken as evidence for corticospinal dysfunction
(Watts et al., 1982; Jan, 2004).
The third factor contributing to the varied descriptions of
the motor syndrome in the published literature on LND is
related to mood lability and anxiety. Patients with LND are
more anxious than other children with developmental dis-
abilities. In some, emotional lability is pronounced, including
some with overt panic attacks. Anxiety and mood lability are
particularly prominent when the patient encounters a stran-
ger, such as a new care-giver or examiner. The heightened
anxiety makes choreoathetosis and ballismus more apparent.
Anxiety and mood lability lessen as the patients become
accustomed to the evaluators, so the examination features
may change during a long visit or over several visits. Con-
sequently, even a single examiner can form different impres-
sions on the basis of serial evaluations of the same patient.
This problem was minimized in the current series because
evaluations were conducted over a lengthy visit or the
patients encountered the same evaluator during multiple
visits over several years.
A last reason for the inconsistent descriptions of motor
abnormalities in LND is that some characteristics of the dis-
ease may vary with development and ageing. There are no
studies that have specifically addressed the natural history
Table 5 Neuroimaging in LND
No of cases Ages (years) Imaging method Reported findings Reference
1 2 CT Normal Salman et al. (1987)
4 2–10 MRI Two normal, one with atrophy,
one with decreased T2 signal
in basal ganglia
Jankovic et al. (1988)
2 4–6 Pneumoencephalography Both normal Michener (1967)
1 5 CT Mild atrophy Hara et al. (1982)
1 7 CT Normal van Bogaert et al. (1992)
1 8 CT Normal Hatanaka et al. (1990)
1 8 Pneumoencephalography Cerebral atrophy Lesch and Nyhan (1964)
1 9 Pneumoencephalography Atrophy Sass et al. (1965)
12 10–20 MRI All normal Ernst et al. (1996)
1 11 CT Normal Marmattom (2005)
1 15 CT and MRI Normal Lynch and Noetzel (1991)
1 19 MRI Normal Taira et al. (2003)
1 21, 29 CT twice Mild atrophy on second scan only Saito and Takashima (2000)
7 22–35 Quantitative MRI Only two showed visible atrophy but
volumetric studies revealed cerebral
volumes reduced 17%
Harris et al. (1998);
Wong et al. (1996)
3 NR CT Normal Watts et al. (1982)
12 NR CT Two with mild atrophy Wong (1988)
One patient had two CT scans separated by 8 years, and atrophy was apparent only on the second one (Saitoh and Takashima, 2000).
NR = not reported.
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with longitudinal studies, but the available evidence suggests
a stereotypical pattern of progression with hypotonia and
developmental delay early in the first year of life. Other invo-
luntary movements emerge later, between 6 and 24 months of
age. Once established, significant progression of the severity
of the motor syndrome with further ageing is uncommon,
though progression of disability from long-standing dystonia
became more apparent, for example as contractures or
scoliosis.
The evolution of the motor syndrome parallels the evolu-
tion of the cognitive disability in LND. Patients with
LND exhibit mild or moderate mental retardation with
Table 6 Neuropathology in LND
Case Age (year : month) Cause of
death
Brain
mass (g)
Reported findings Reference
1 0 : 11 NR NR Cortical neuron loss and
superficial gliosis
Crome and Stern (1967)
2 1 : 9 NR NR Severe hydrocephalus with
degeneration and gliosis of the
cerebrum and medulla
Wada et al. (1968)
3 2 : 10 Seizures and
opisthotonic
spasms
850 Two small softenings in parietal
lobe and brainstem
Hoefnagel et al. (1965)
4 3 : 4 Respiratory
infection
NR Thin cortex with dilation of
the left lateral ventricle
Storey (1969)
5 3 : 6 NR 1120 Normal Crussi et al. (1969)
6 3 : 8 NR 960 Focal degenerative changes in
unspecified areas
Mahnovski et al. (1975)
7 4 : 0 NR NR Cortical neuron loss, superficial
gliosis, multiple foci of cerebellar
necrosis
Crome and Stern (1967)
8 5 : 0 Pneumonia 1120 Tiny birefringent crystals in
perivascular spaces
Partington and Hennen (1967)
9 6 : 0 NR NR Normal Watts et al. (1987)
10 6 : 2 NR 1038 Normal Crussi et al. (1969)
11 7 : 0 Febrile illness 1180 Discrete cerebral oedema Bassermann et al. (1979)
12 10 : 0 Pneumonia NR Focal areas of gliosis in
cerebellum
Mitchell and McInnes (1984)
13 11 : 0 Uraemia with
septicaemia
950 Diffuse vascular and demyelinative
lesions of the white matter, degeneration
of cerebellar granule cells, multiple
foci of gliosis
Sass et al. (1965)
14 13 : 0 NR 880 PAS-positive and Sudan-negative
inclusions in the olives
Warzok et al. (1982)
15 14 : 0 NR NR Normal Watts et al. (1987)
16 15 : 0 Cardiopulmonary
arrest
NR Mild gliosis with increased
medium spiny neurons in caudate and
putamen, normal pigmented neurons in
midbrain, low-normal midbrain neurons
positive for TH
Saito et al. (1999)
17 15 : 4 Broncho-pneumonia 1100 Small softenings in cerebellum,
chromatolysis of Purkinje cells,
degeneration in dentate, diffuse foci
of necrosis and gliosis in white
matter
Mizuno (1986);
Mizuno et al. (1976)
18 32 : 0 Pneumonia NR Mild gliosis in tegmentum and cerebellar
white matter, reduced pigmented
neurons in midbrain, low-normal
midbrain neurons positive for TH
Saito et al. (1999)
19 NR NR NR Normal Hoefnagel (1968)
20 NR NR NR Thinning of the cerebellar cortex Hoefnagel (1968)
21 NR NR NR Reduced spine density on occipital
neurons
Saito and Takashima (2000)
22 NR NR NR Non-specific changes compatible
with an anoxic mode of death
Watts et al. (1982)
One case was reported as LND without confirmatory laboratory findings and had atypical features of congenital blindness and marked
ventricular dilation (Wada et al., 1968), raising some uncertainty regarding the diagnosis. NR = not reported.
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slow learning in school, but there is no evidence for progres-
sive dementia with ageing (Anderson et al., 1992; Matthews
et al., 1995; Solan et al., 1997; Schretlen et al., 2001). The
evolution of motor and cognitive impairments in LND
resembles that seen in cerebral palsy. The early changes of
the motor features may reflect the response of the developing
brain to a static insult rather than an ongoing pathological
process (Almli and Finger, 1984; Finger and Almli, 1984).
Although LND is often classified in texts and reviews of
movement disorders among the ‘heredodegenerative’ dysto-
nias, it is more appropriately classified among the ‘dystonia-
plus’ syndromes, in view of the absence of obvious progres-
sion and the lack of evidence for a degenerative process.
Several clinical phenomena observed in LND may be con-
sidered in the context of other movement disorders where
dystonia is well recognized. Severe opisthotonus with coarse
whole-body shaking was frequent in the current series and in
the literature on LND. This phenomenon is sometimes mis-
taken for epileptic seizures, but it is also seen in many move-
ment disorders, where it is best characterized as a truncal
dystonia with dystonic tremor (Fricka et al., 2001; Jan,
2004). The oromandibular and lingual dystonia in LND
is similar to that seen in neuro-acanthocytosis (Hardie,
1989) or tardive syndromes due to chronic exposure to dopa-
mine receptor antagonists (Tan and Jankovic, 2000). It is
interesting that self-injurious tongue biting, a nearly universal
phenomenon in LND, is seen occasionally in neuro-
acanthocytosis or tardive syndromes too (Jankovic, 1988).
The inspiratory stridor that occurs during wakefulness but
not sleep in several LND patients is similar to that reported
as laryngeal breathing dystonia (Grillone et al., 1994) and in
some cases of multiple system atrophy (Merlo et al., 2002).
This observation may provide a clue for understanding LND
patients who exhibit recurrent apnoea or even sudden death.
Finally, patients with LND exhibit ocular motor apraxia char-
acterized by delayed initiation of voluntary saccades with
facilitation of reflexive saccades similar to that observed in
several other extrapyramidal disorders (Jinnah et al., 2001).
These additional manifestations further emphasize the extra-
pyramidal nature of the motor disorder of LND.
Pathophysiology of the motor disorder
The motor syndrome of LND described in the present series is
consistent with current knowledge regarding the pathophy-
siology of the disorder. Overall, the most frequent abnorm-
ality among the imaging (Table 5) and autopsy studies
(Table 6) has been a reduction in brain volume. This reduc-
tion in volume, however, seems often small enough to escape
notice in routine studies. Routine imaging studies are there-
fore not particularly helpful in the evaluation of these
patients.
Although consistent anatomical defects in LND brains
have not been apparent, biochemical and PET studies have
demonstrated abnormalities of basal ganglia dopamine
systems. Biochemical studies of five LND brains have
documented a profound loss of dopamine and its metabolites
in the basal ganglia (Lloyd et al., 1981; Saito et al., 1999).
Dopamine was not significantly reduced in the midbrain,
fuelling speculation that midbrain dopamine neurons were
preserved but that their axonal projections to the basal gang-
lia failed to develop or degenerated. In support of this pro-
posal, midbrain dopamine neurons identified by Nissl stains
or by immunostaining for tyrosine hydroxylase did not
appear to be reduced in numbers in two cases (Saito et al.,
1999). Furthermore, two PET studies have confirmed severe
abnormalities of dopaminergic fibres in the basal ganglia. In
one study, the accumulation of [18F]fluorodopa into mono-
aminergic axons in the striatum was reduced by 60–70% in
11 LND patients (Ernst et al., 1996). In the other study, the
binding of [11C]WIN 35 428 to dopamine uptake sites on
dopamine axons was reduced by a similar amount in seven
other patients (Wong et al., 1996). These studies suggest a
severe loss of dopaminergic axons in LND, though histolo-
gical evidence is currently lacking.
These biochemical and PET data are consistent with the
prominent dystonia observed in LND (Visser et al., 2000). A
profound loss of striatal dopamine most often causes parkin-
sonism in adults, but more frequently causes dystonia in
children. For example, early dopamine loss associated with
inherited deficiency of GTP cyclohydrolase or tyrosine hydro-
xylase is more often associated with dystonia rather than
parkinsonism (Perlmutter and Mink, 2004). Experimental
studies have also shown that the age at which striatal dopa-
mine depletion occurs has a dramatic influence on motor
function in rodents. In adult rats, destruction of 95% of
nigrostriatal dopamine neurons results in a motor syndrome
resembling parkinsonism (Hirsch et al., 2003). In contrast,
the same lesion in neonatal rats results in spontaneous hyper-
activity and aggressiveness without signs of parkinsonism
(Moy et al., 1997).
Isolated dysfunction of striatal dopamine systems does not
account for the pyramidal signs that appear in some cases.
Even recognizing the possibility of misclassification of neu-
rological signs, another possibility is that HPRT deficiency
causes dysfunction in corticospinal motor systems, although
evidence currently is lacking. Another possibility is that cor-
ticospinal tract signs reflect an indirect, acquired process. The
observation that the corticospinal tract signs frequently are
limited to the legs suggests the possibility of cervical myelo-
pathy, perhaps secondary to degenerative changes of the
cervical spine caused by cervical dystonia with retrocollis.
In fact, cervical instability leading to myelopathy has
been documented for two LND patients (Watts et al.,
1982). Violent retrocollis caused atlantoaxial dislocation in
another case (Hoefnagel et al., 1965). A non-traumatic high
cervical fracture in one case, and an os odontoideum in
another, could both have resulted from chronic and
forceful involuntary movements of the neck (Shewell and
Thompson, 1996).
The possibility that cervical myelopathy results from invo-
luntary neck movements is not unique to LND, but has been
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described in several other conditions, including cervical
dystonia, generalized dystonia, paroxysmal dystonia, dyski-
netic cerebral palsy and Tourette syndrome (Anderson et al.,
1962; Levine et al., 1970; Hirose and Kadoya, 1984; Ebara
et al., 1989; El-Mallakh et al., 1989; Adler et al., 1996; Harada
et al., 1996; Krauss and Jankovic, 1996; Rosenfeld and
Friedman, 1999). Since baseline motor disability is often
quite severe in LND, the potential development of a second-
ary myelopathy can be difficult to identify. Further studies are
needed to clarify the source of the pyramidal signs in LND.
Until this information is available, it is prudent to perform
imaging studies of the cervical or thoracic spine in LND
patients who develop true corticospinal signs.
Treatment
Although several trials have addressed the treatment of
self-injury, there have been no controlled trials devoted to
treatment of the motor disorder in LND. Anecdotal reports
of dopamine replacement with levodopa in 11 patients
described mixed results (Mizuno and Yugari, 1974;
Mizuno and Yugary, 1975; Watts et al., 1982; Manzke
et al., 1986; Jankovic et al., 1988; Hunter et al., 1996).
Mild improvement was noted for six, mild worsening was
noted for three and no effect was reported for two. There is
a single report of two patients involving the use of a direct-
acting dopamine agonist, bromocriptine, again with mixed
results (Jankovic et al., 1988). The interpretation of these
results is complicated by two issues. First, the maximal
doses employed and the duration of therapy were recorded
only rarely. Second, several investigators have suggested that
some of the dyskinetic movements and even self-injury in
LND might reflect a form of ‘endogenous’ dopamine-related
dyskinesia (Proctor and McGinness, 1970; Taira et al., 2003).
It is therefore possible that dopaminergic drugs reduce the
severity of dystonia while simultaneously increasing other
involuntary movements or distressing behaviours, rendering
a negative overall impression of the treatment response.
Further trials with more detailed observations of the influence
of specific doses of these agents on different aspects of the
condition are warranted.
Others have tried the dopamine-depleting agent tetrabe-
nazine (Watts et al., 1974; Jankovic et al., 1988). Efforts to
control self-injurious behaviours often lead to the use of
dopamine receptor antagonists including pimozide, haloper-
idol, fluphenazine and Risperdal (Watts et al., 1982;
Goldstein et al., 1985; Jankovic et al., 1988; Allen and Rice,
1996). Their benefits on self-injury are unreliable, and they do
not appear to have a significant influence on dystonia. We
prefer to avoid these drugs as they carry the risk of causing
tardive syndromes that make assessment and management of
the pre-existing motor disorder unnecessarily complicated.
Oral baclofen and benzodiazepines are often prescribed
for patients with LND. While they may be useful for con-
trolling spasticity and clonus in the minority of patients who
have these problems, their value in the management of the
extrapyramidal features is unclear. Two of our patients
received intrathecal baclofen pumps. Both reported good
results, though objective assessments were not possible
because the procedures were performed before our evalua-
tions. There was a notable paucity of reports describing
results of treatment with trihexyphenidyl or other anticholi-
nergics. In our experience, it is not useful in non-sedating
doses. However, botulinum toxins can be used to treat some
of the most discomforting manifestations, such as cervical or
limb dystonia.
Finally, there are two case reports of thalamotomy produ-
cing little or no improvement (Michener, 1967; Bunn et al.,
1975) and another case report describing 30% improvement
in dystonia following chronic deep brain stimulation of the
globus pallidus in LND (Taira et al., 2003). In the last case, an
unexpected benefit was complete elimination of self-injurious
behaviours for at least one year. Further studies of these
procedures are required before they can be recommended
to all patients.
Summary
The motor disorder of LND characteristically presents with
hypotonia and/or delayed acquisition of motor skills within
the first 3–6 months of age. Additional involuntary move-
ments, most prominently dystonia, usually develop between
6 and 24 months of age. Other extrapyramidal and pyramidal
signs may occur, but these are usually minor compared with
dystonia. The more varied descriptions of the motor syn-
drome in the literature probably reflect differences in the
use of movement disorder terminology, poor recognition
of the many different manifestations of dystonia and influ-
ences related to age and anxiety at the time of evaluation. The
processes whereby a defect in HPRT-mediated purine recy-
cling leads to the neurobehavioural manifestations remain
largely unknown, but a growing body of evidence has pointed
to dysfunction of basal ganglia dopamine systems as a poten-
tial underlying contributor to dystonia. Current treatments
are not satisfactory. Increasing our understanding of the
pathophysiology of LND may allow for the rational design
of new approaches for treatment.
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